EMTRIVA NEWS HIGHLIGHTS
Media Articles Related to Emtriva (Emtricitabine)
HIV Infection Rate for Young Black Men 'Alarming:' CDC
Source: MedicineNet Mens Health Specialty [2008.09.12]
Scientists Spot New Twist in HIV Infection
Source: MedicineNet Sexually Transmitted Diseases (STDs In Women) Specialty [2008.09.05]
Herpes Suppression May Not Prevent HIV Infection
Source: MedicineNet Genital Herpes In Women Specialty [2008.06.20]
HIV's Genetic 'Flight Plan' Filed
Source: MedPage Today Infectious Disease [2008.10.02]
Published Studies Related to Emtriva (Emtricitabine)
Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine. [2008.03]
Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. [2007.11.17]
Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. [2007.08]
Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. [2007.07]
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. [2006.12.15]
Clinical Trials Related to Emtriva (Emtricitabine)
An Open-Label Study of Emtricitabine in Combination With Other Antiretroviral Agents in HIV Infected Pediatric Subjects [Completed]
A 96 Week Study to Compare Tenofovir Versus Tenofovir Plus Emtricitabine for the Treatment of Chronic Hepatitis B [Active, not recruiting]
Tenofovir DF (Disoproxil Fumarate) in Combination With Emtricitabine in HIV-1 Patients [Completed]
Tenofovir Disoproxil Fumarate (DF)/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects [Active, not recruiting]
The Safety and Effectiveness of 524W91 [Completed]
|
